导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.36% | 1894/4773 |
| 近一周 | -3.14% | 3755/5462 |
| 近一月 | -9.85% | 4888/5421 |
| 近一季 | -18.44% | 4700/5209 |
| 近半年 | -1.58% | 1640/4920 |
| 近一年 | 5.60% | 1576/4366 |
| 近两年 | 105.33% | 549/2954 |
| 近三年 | 61.78% | 418/2253 |
| 成立以来 | 139.15% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.79% 1961/4961 |
34.33% 955/5312 |
- - |
- - |
| 2025 | 47.67% 558/4813 |
-1.59% 2704/3635 |
3.11% 1158/4076 |
47.21% 474/4524 |
-1.14% 2847/4813 |
| 2024 | 13.73% 1110/3463 |
-3.41% 1500/2808 |
-6.35% 1920/3014 |
27.53% 219/3129 |
-1.40% 1688/3463 |
| 2023 | -17.81% 1760/2656 |
2.05% 1460/2280 |
-6.75% 1697/2385 |
-9.08% 1775/2515 |
-5.01% 1234/2655 |
| 2022 | -27.49% 1483/2207 |
-18.98% 1417/1919 |
5.85% 815/2016 |
-17.45% 1598/2113 |
2.43% 940/2208 |
| 2021 | 14.66% 326/1822 |
-5.71% 948/1255 |
25.66% 84/1330 |
-5.54% 820/1466 |
2.45% 592/1822 |
| 2020 | 64.95% 96/1250 |
4.63% 64/1028 |
28.53% 100/1067 |
6.47% 837/1164 |
15.20% 227/1184 |
| 2019 | 41.85% 228/1092 |
32.78% 161/739 |
-8.96% 622/788 |
7.30% 94/850 |
9.36% 232/918 |
| 2018 | - - |
- - |
- - |
- - |
-10.06% 176/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华夏创业板ETF联接A VS. 长安沪深300非周期A(740101) |